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he addition of clopidogrel to aspirin treatment reduces ischemic events in a wide
ange of patients with cardiovascular disease. However, recurrent ischemic event occurrence
uring dual antiplatelet therapy, including stent thrombosis, remains a major concern. Platelet
unction measurements during clopidogrel treatment demonstrated a variable and overall modest
evel of P2Y12 inhibition. High on-treatment platelet reactivity to adenosine diphosphate (ADP)
as observed in selected patients. Multiple studies have now demonstrated a clear association
etween high on-treatment platelet reactivity to ADP measured by multiple methods and adverse
linical event occurrence. However, the routine measurement of platelet reactivity has not been
idely implemented and recommended in the guidelines. Reasons for the latter include: 1) a lack
f consensus on the optimal method to quantify high on-treatment platelet reactivity and the
utoff value associated with clinical risk; and 2) limited data to support that alteration of therapy
ased on platelet function measurements actually improves outcomes. This review provides a
onsensus opinion on the definition of high on-treatment platelet reactivity to ADP based on
arious methods reported in the literature and proposes how this measurement may be used in
he future care of patients.
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High On-Treatment Platelet Reactivity September 14, 2010:919–33latelet activation and aggregation play pivotal pathophys-
ological roles in the development of ischemic events during
nd after acute coronary syndromes (ACS) and percutane-
us coronary interventions (PCIs) (1). Adenosine diphos-
hate (ADP) is a major secondary agonist released from the
ense granules of platelets activated by primary agonists
Fig. 1). The ADP-P2Y12 receptor interaction plays a
entral role in the sustained activation of glycoprotein (GP)
Ib/IIIa receptors leading to stable platelet-rich thrombus
eneration at the site of vessel wall injury (2). Therefore,
lopidogrel, whose active metabolite irreversibly inhibits the
2Y12 receptor, is a cornerstone of oral antiplatelet therapy
n the secondary prevention of coronary artery disease and in
he immediate treatment of ACS and PCI (3).
A significant reduction in ischemic complications in a
ide range of coronary artery disease patients has been
emonstrated in major randomized controlled trials by
dding clopidogrel to aspirin treatment (4,5). The fixed
ose, “one size fits all” treatment strategy with clopidogrel
herapy, which has been used in clinical trials and recom-
ended by current guidelines, does not take into account
he interindividual pharmacodynamic variability of clopi-
ogrel therapy (4–6). Moreover, despite the relatively
otent antiplatelet effect of clopidogrel in some patients,
thers will suffer therapeutic failure manifested by ischemic
vents, including stent thrombosis, that have been associ-
ted with high on-treatment platelet reactivity (7).
These observations have stimulated intensive research of
he pharmacodynamic and pharmacokinetic properties of
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010, accepted April 5, 2010.lopidogrel. Studies measuring platelet function in patients
dministered clopidogrel revealed that, unlike aspirin and
P IIb/IIIa receptor blocker therapies that are associated
ith a uniform and high level of inhibition (95%) of their
argets (COX-1 enzyme and GP IIb/IIIa receptor, respec-
ively) with appropriate dosing in particular for GP IIb/IIIa
nhibitors, clopidogrel treatment is associated with an over-
ll variable and modest level of P2Y12 inhibition even when
igh loading doses are used (4,6,8–10). In addition to
istinct response variability, a substantial percentage of
atients will also exhibit complete nonresponsiveness (resis-
ance) to clopidogrel (10).
Multiple studies now have demonstrated a relationship
etween clopidogrel nonresponsiveness and/or high on-
reatment platelet reactivity measured by multiple platelet
ssays and adverse clinical ischemic events (7). However,
ue to a lack of consensus on the optimal methods to
uantify high platelet reactivity and the cutoff values asso-
iated with clinical risk, the routine measurement of platelet
eactivity has not been widely implemented in clinical
ractice nor recommended in the guidelines (11). In addi-
ion, there are only limited data to support the concept that
lterations of therapy based on platelet function measure-
ents improve clinical outcome (7).
Herein, we provide a comprehensive overview of the
vailable data that have identified high on-treatment plate-
et reactivity to ADP as a risk factor for post-PCI ischemic/
hrombotic events as well as a consensus opinion on the
efinition of high on-treatment platelet reactivity to ADP
ased on the primary methods reported in the literature.
lopidogrel Metabolism
lopidogrel is a prodrug that requires hepatic conversion
nto an active metabolite to exert its antiplatelet response.
ost of absorbed clopidogrel (85% to 90%) is hydrolyzed
y carboxylase to an inactive carboxylic acid metabolite,
R26334, whereas the remaining 10% to 15% is rapidly
etabolized by hepatic cytochrome (CYP) P450 isoen-
ymes in a 2-step process. In the first step, the thiophene
ing of clopidogrel is oxidized to 2-oxo-clopidogrel, which
s then hydrolyzed to a highly labile active metabolite,
-130964, that has both carboxylic acid and thiol groups
12–14). Recent studies indicate that CYP2C19, CYP1A2,
nd CYP2B6 participate in the first metabolic step, whereas
YP2C19, CYP2C9, CYP2B6, and CYP3A are responsi-
le for the second step (12,13) (Fig. 2). The highly unstable
ctive metabolite, R-130964, covalently binds to platelet
2Y12 receptor specifically and irreversibly during passage
hrough the hepatic circulation resulting in inhibition of
DP-induced platelet activation-aggregation for the life
pan of the platelet (15). This metabolic activation scheme
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September 14, 2010:919–33 High On-Treatment Platelet Reactivitys consistent with the time-dependent cumulative inhibition
f ADP-induced platelet aggregation as observed with
epeated daily dosing of clopidogrel and is further high-
ighted by slow recovery of platelet function following drug
ithdrawal (4,16,17).
Multiple lines of evidence strongly suggest that variable
nd insufficient active metabolite generation are the primary
xplanations for clopidogrel response variability and nonre-
ponsiveness, respectively (9). Variable levels of active me-
abolite generation following clopidogrel administration
ould be explained by: 1) variable or limited intestinal
bsorption, which may be affected by an ABCB1 gene
olymorphism (18–20); 2) functional variability in P450
soenzyme activity influenced by drug-drug interactions as
ell as other factors; and 3) single nucleotide polymor-
hisms of specific genes encoding CYP450 isoenzymes
21,22). Stimulation of CYP3A4 activity by rifampin and
t. John’s wort and CYP1A2 activity by tobacco smoking
ave both been shown to enhance platelet inhibition in-
uced by clopidogrel (23–25). The effect of smoking on the
ntiplatelet effect of clopidogrel has been associated with
Figure 1
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hese agents, the consequence of these interactions with respect
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Recent studies have evaluated the influence of the single
ucleotide polymorphisms of genes encoding CY2C19
soenzymes with different activities, as well as single nucle-
tide polymorphisms of the p-glycoprotein transporter gene
n clopidogrel response variability and clinical outcomes
22,32). Multiple independent studies have demonstrated a
ink between the presence of genetic polymorphisms asso-
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ogrel responsiveness as measured by platelet function
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High On-Treatment Platelet Reactivity September 14, 2010:919–33cal outcomes. No single study has conclusively associated all
f these parameters in the same patient population. More-
ver it was observed that other genetic determinants may be
nvolved and that overall, 12% of the variation in the
esponse to clopidogrel can be attributed to the CYP2C19*2
oss-of-function allele (33). At this time, it is uncertain
hether the factors associated with a poor response to
lopidogrel are additive in diminishing the antiplatelet effect
f clopidogrel and worsening patient outcomes.
The controversy surrounding the diminished effectiveness
f clopidogrel in poor metabolizers (those having 2 loss-of-
unction CYP2C19 alleles) and the utility of genetic tests to
dentify differences in CYP2C19 function has been recently
ighlighted by the “boxed warning” issued by the Food and
rug Administration advising health care professionals to
onsider use of other antiplatelet medications or alternative
osing strategies for clopidogrel in these patients (34). The
receding statement was based on observations from a study
f 40 healthy subjects that poor metabolizers had dimin-
shed active metabolite exposure and higher platelet aggre-
Figure 2
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September 14, 2010:919–33 High On-Treatment Platelet ReactivityHARISMA investigated a lower-risk population and was
ot a study of stented patients. The CHARISMA Genomics
tudy investigators pointed out 2 important caveats: 1) poor
etabolizers in the placebo arm also had an increased risk;
ut 2) only a small number of primary events occurred in poor
etabolizers (placebo arm, n 5 [8.77%] and clopidogrel arm,
 8 [13.79%]). The CHARISMA Genomics study (39) is
he only investigation in which the influence of genotyping on
linical outcome was studied in both the clopidogrel arm and
he placebo arm.
Moreover, the safety and efficacy of altering therapy in
esponse to genotype is entirely unknown. Whereas neither
enotyping nor platelet function tests alone adequately
escribe the global risk profile of an individual patient
reated with clopidogrel, point-of-care platelet function
esting to identify high-risk patients combined with
YP2C19 genetic testing may be more effective in identi-
ying high-risk individuals for alternative antiplatelet ther-
pies. Ultimately, prospective randomized clinical trials will
e needed to test specific personalized antiplatelet algo-
ithms to provide the evidence base necessary for widespread
doption into clinical practice.
In addition to the preceding mechanisms for clopidogrel
harmacodynamic variability, increased body mass index,
iabetes mellitus, and acute coronary syndromes have also
een associated with a diminished antiplatelet response to
lopidogrel (40–42). Several studies have demonstrated the
oexistence of clopidogrel and aspirin resistance in the same
atient population (43,44). It has also been demonstrated
hat patients with low responsiveness to a 600-mg loading
ose, in addition to exhibiting a low level of inhibition of
DP-induced aggregation, also exhibit lower inhibition of
ggregation induced by collagen and thrombin receptor
gonist peptide as compared to moderate and high clopi-
ogrel responders (45). Taken together, these data support
he existence of a “hypo-responsive” or global high platelet-
eactivity phenotype. Patients with the latter phenotype will
ave platelets that react robustly to multiple agonists.
inally, noncompliance is an obvious factor that must be
xcluded in the diagnosis of clopidogrel nonresponsiveness.
hen attempting to define causality for high platelet
eactivity related to the occurrence of clinical events in
atients receiving clopidogrel, all of the aforementioned
echanisms should be considered.
oncept of Clopidogrel
onresponsiveness, Resistance, and
igh On-Treatment Platelet Reactivity
single treatment strategy directed against a specific
eceptor cannot be expected to overcome all thrombotic
vents, and clinical treatment failure (occurrence of an ischemic event) during clopidogrel treatment is not synon-
mous with clopidogrel resistance. The optimal definition
f resistance or nonresponsiveness to any antiplatelet agent
hould be the failure of the antiplatelet agent to inhibit the
arget of its action (7). The identification of resistance
hould therefore utilize a laboratory technique that detects
he activity of the target receptor before and after adminis-
ration of the specific antiplatelet agent. For example, the
bsence of a change in platelet response (reactivity) to ADP
rom baseline after clopidogrel intake is an indicator of
lopidogrel resistance. Earlier studies that measured light
ransmission platelet aggregation used an absolute difference
f 10% aggregation as the definition of clopidogrel resis-
ance (baseline vs. on-treatment) (6,7). Patients were also
ategorized as “nonresponsive,” “semiresponsive,” and “re-
ponsive” using absolute platelet inhibition cut points of
10%, 10% to 30%, and 30%, respectively (6,46).
Even though a measurement of responsiveness (absolute or
elative changes in platelet aggregation from baseline) appears
s the most reliable indicator of a treatment effect, it may not
e the optimal method to identify patients at high risk. Given
he interindividual variability in baseline ADP-induced platelet
ggregation, the measurement of clopidogrel responsiveness
inhibition) may overestimate ischemic risk in nonresponders
ith low pre-treatment reactivity as well as underestimate risk
n responders who remain with high platelet reactivity after
reatment (47,48). Therefore, the absolute level of platelet
eactivity during treatment (i.e., on-treatment platelet reactiv-
ty) has been proposed as a better measure of thrombotic risk
han responsiveness to clopidogrel.
The relationship of on-treatment platelet reactivity to
oth periprocedural and long-term ischemic risk has been
ost widely investigated. However, the optimal method to
uantify platelet reactivity as well as the threshold definition
or high on-treatment platelet reactivity to ADP have been
ubjects of controversy. Another concern surrounds the
iming of platelet reactivity measurement that is optimally
ssociated with short- and long-term risk. Any definition of
igh on-treatment platelet reactivity will only be meaningful
hen a cutoff or target value is identified by an accepted
tatistical test. Most commonly, the receiver-operator char-
cteristic (ROC) curve analysis has been used to define the
ptimal cut point definition of high on-treatment platelet
eactivity associated with ischemic risk. This method allows
s to determine the cutoff value of platelet reactivity that
ould be associated with the lowest false negative and false
ositive rates and thus provides the greatest sum of sensitivity
nd specificity. The ROC curve analysis has been used to
efine cut points currently employed in prospective studies of
ndividualized antiplatelet therapy in PCI patients (49).
M
t
B
e
i
h
e
i
a
f
t
r
C
p
c
f
c
c
m
g
a
b
s
h
s
c
b
t
t
o
d
f
p
s
g
o
b
f
p
t
d
m
P
b
D
I
A
r
a
p
M
p
P
u
i
i
t
p
r
P
e
a
r
t
m
r
C
O
J
r
d
fi
d
u
e
3
d
b
t
p
(
i
e
n
v
t
c
p
(
b
p
u
c
L
a
N
t
924 Bonello et al. JACC Vol. 56, No. 12, 2010
High On-Treatment Platelet Reactivity September 14, 2010:919–33ethods to Assess Platelet Responsiveness
o ADP and P2Y12 Receptor Reactivity
ecause clopidogrel specifically inhibits the P2Y12 receptor,
x vivo measurement of ADP-induced platelet aggregation
n platelet-rich plasma by light transmittance aggregometry
as been the most commonly used laboratory method to
valuate platelet inhibition by clopidogrel and its relation to
schemic risk. In the strictest sense, aggregometry evaluates
n integrated response of the platelet to ADP through the
unction of both P2Y1 and P2Y12 receptors. In most studies,
he maximal amplitude of measured platelet aggregation in
esponse to 5-, 10-, or 20-mol/l ADP has been recorded.
itrate remains the most widely used anticoagulant during
latelet function testing, although it affects intracellular
alcium ion concentrations, which may influence platelet
unction. Alternatively, D-phenylalanyl-L-prolyl-L-arginine
hloromethyl ketone or hirudin may be used to reduce
hanges in calcium ion concentrations. In addition to
aximum platelet aggregation, late (final or residual) ag-
regation measured 5 to 6 min after the addition of agonist,
time when platelet disaggregation normally appears, has
een proposed as a better indicator of clopidogrel respon-
iveness. Although Collet et al. (20) and Labarthe et al. (50)
ave correlated late aggregation with the antiplatelet re-
ponse to clopidogrel, Gurbel et al. (51) suggested that
lopidogrel nonresponders may be similarly identified by
oth maximal and late aggregation. Although some inves-
igators have advocated the adjustment of platelet concen-
ration in plasma to 250,000/mm3 before measuring,
thers have suggested that such an adjustment may intro-
uce artifacts and contribute to assay variability (52). Un-
ortunately, because many other procedures involved in the
erformance of light transmittance aggregometry are not
tandardized between institutions, light transmittance ag-
regometry may not be the ideal test to monitor the effects
f antiplatelet therapy outside of clinical trials (53).
Flow cytometric measurements of platelet expression of
oth activated GP IIb/IIIa receptor and P-selectin (CD62)
ollowing ADP stimulation in addition to ADP-induced
latelet-fibrin clot strength as measured by whole blood
hrombelastography have also been used to identify clopi-
ogrel nonresponsiveness. Thrombelastography measure-
ents correlated platelet function with ischemic risk in the
CI population (54,55). In addition, 2 point-of-care whole
lood assays, the VerifyNow P2Y12 assay (Accumetrics, San
iego, California) and the Multiplate analyzer (Dynabyte
nformationssysteme, Munich, Germany) (both employing
DP as the agonist) have been used to measure platelet
eactivity during clopidogrel therapy. The VerifyNow P2Y12
ssay is a turbidimetric assay that measures aggregation of
latelets to fibrinogen-coated beads in whole blood. The eultiplate analyzer is an impedance aggregometer that assesses
latelet function in whole blood. The platelet function analyzer
FA-100 (Dade Behring, Deerfield, Illinois) method, which
tilizes collagen/ADP-based cartridges and measures shear-
nduced platelet aggregation, has been associated with
nconsistent estimates of platelet reactivity to ADP. Finally,
he phosphorylation state of vasodilator-stimulated phos-
hoprotein (VASP) is a specific intracellular marker of
esidual P2Y12 receptor reactivity in patients treated with
2Y12 blockers, which is currently measured by flow cytom-
try and has also been correlated with ischemic risk (7). In
ddition, this is the only test that specifically assesses P2Y12
eceptor activity. Unlike methods employing the aggrega-
ion induced by ADP, in VASP, phosphorylation assay
easurement does not include the contribution of the P2Y1
eceptor to the overall response (56).
lopidogrel Nonresponsiveness and
n-Treatment Platelet Reactivity: Early Studies
äremo et al. (57) first reported interindividual variability in
esponse to clopidogrel in patients with coronary artery
isease by using flow cytometry to detect ADP-induced
brinogen binding to platelets. Gurbel et al. (6) first
emonstrated clopidogrel response variability and resistance
sing conventional platelet aggregometry and flow cytom-
try studies in patients undergoing PCI who had received a
00-mg loading dose followed by 75-mg daily maintenance
ose of clopidogrel. The level of platelet inhibition induced
y clopidogrel was dependent on the time after clopidogrel
reatment when platelet function was measured and the
revalence of resistance fell from 31% (days 1 and 5) to 15%
day 30). Importantly, although a 600-mg clopidogrel load-
ng dose is associated with more potent platelet inhibitory
ffects than a 300-mg dose, this higher-dose regimen was
ot able to completely overcome resistance, and a broad
ariability in response profiles continued to persist (8,9). In
he Gurbel et al. studies (6,8), pharmacologic resistance to
lopidogrel was defined as an absolute 10% decrease in
latelet aggregation in response to agonist from baseline
pre-treatment measurement). Based on these studies, it
ecame similarly apparent that the level of post-treatment
latelet reactivity during clopidogrel therapy was largely
npredictable. Only early platelet reactivity (24 h after PCI)
orrelated with pre-treatment platelet reactivity (6).
ink Between High Platelet Reactivity
nd Post-PCI Ischemic/Thrombotic Events
umerous studies have reported pharmacological “resis-
ance” to clopidogrel as a potential etiology for thrombotic
vents after PCI (Table 1) (43,54–83). Barragan et al. (58)
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September 14, 2010:919–33 High On-Treatment Platelet Reactivityere the first to demonstrate an association between post-
reatment platelet reactivity and the occurrence of throm-
otic events (clinical treatment failure) in a case-control
tudy of PCI patients. In the study by Barragan et al. (58),
platelet reactivity index (PRI) 50% measured by VASP-
hosphorylation assay was associated with thrombotic risk.
f note, in this study, turbidimetric aggregation was not
ssociated with ischemic risk. However, at the same time,
atetzky et al. (59), using aggregometry, observed that
atients undergoing primary PCI for ST-segment elevation
yocardial infarction who were in the lowest quartile of
lopidogrel responsiveness had the highest rates of ischemic
vents during follow-up.
Subsequently, it was suggested that the level of on-
reatment platelet reactivity might be a superior risk predictor
ompared with the difference between baseline and post-
reatment platelet reactivity, because platelet reactivity to ADP
as variable before clopidogrel treatment in patients on aspirin
herapy (47,48). The important relationship between high
n-treatment platelet reactivity to ADP as measured by turbi-
imetric aggregometry and the occurrence of ischemic events
n patients treated with stents was first prospectively demon-
trated in the PREPARE POST-STENTING (Platelet Re-
ctivity in Patients and Recurrent Events Post-Stenting)
tudy (upper quartile, odds ratio: 2.6) (55). Multiple subse-
uent studies have confirmed the direct relationship be-
ween the level of platelet reactivity and post-PCI ischemic
vent occurrence using aggregation. Most recently, there
ave been further studies employing the VASP-phosphorylation
ssay, the VerifyNow P2Y12 assay, and the Multiplate ana-
yzer. These studies have consistently demonstrated that high
n-treatment platelet reactivity is an important independent
isk factor for the occurrence of thrombotic/ischemic events
fter PCI (56–84).
igh Platelet Reactivity
efined by ROC Analysis
mportantly, studies have emerged that have used ROC
urve analysis to define a threshold or cut point of on-
reatment platelet reactivity associated with the optimal
ombination of sensitivity and specificity to identify throm-
otic risk (Table 2). Thrombotic events may be prevented
y achieving platelet reactivity below this threshold. It
hould be noted that such cut points might depend on the
ubset of patients studied. In fact, to date, cutoff values have
een mainly investigated in patients undergoing PCI and
ifferent targets may be obtained in other settings depend-
ng on patient management or baseline risk profile (77,78).
Recent studies (62,64,72,76,77) have observed the
rognostic value of the VASP phosphorylation analysis, rith an optimal cutoff value for VASP-PRI between 48%
nd 53%, which is similar to the threshold defined by
arragan et al. (58) in their earlier study of early stent
hrombosis. Although these studies used different ischemic
nd points such as stent thrombosis or major adverse cardiac
vents (e.g., cardiovascular death, myocardial infarction, and
rgent revascularization with or without stroke), they nev-
rtheless found similar cutoff values for the VASP-PRI that
ere associated with post-PCI thrombotic event occur-
ence. Similarly, using the VerifyNow P2Y12 assay, a cutoff
alue of240 P2Y12 reaction units appears to be prognostic
or subsequent thrombotic events (including cardiovascular
eath and stent thrombosis or cardiovascular death, nonfatal
yocardial infarction, and stent thrombosis) (68,78,79,82).
n a recent study, maximal platelet aggregation 46% in
esponse to 5-mol/l ADP following PCI was associated
ith major adverse cardiac events (69). Using the Multiplate
nalyzer, Sibbing et al. (80) demonstrated that high on-
reatment ADP-induced platelet reactivity measured before
CI was associated with the occurrence of 30-day stent
hrombosis in 1,608 patients who had received a 600-mg
lopidogrel loading dose before PCI. Moreover, based on
OC analysis, a cut point of 468 arbitrary aggregation
nits/min (approximately corresponding to the highest
uintile) was associated with the occurrence of stent throm-
osis (80). Recently, Breet et al. (82) evaluated the utility of
ultiple platelet function assays in predicting 1-year out-
ome of death, myocardial infarction, stent thrombosis, and
troke in 1,069 consecutive patients treated with clopidogrel
ollowing elective coronary stent implantation. In this large,
rospective, observational study, high on-treatment platelet
eactivity cut points of 42.9% maximal aggregation induced
y 5-mol/l ADP and 64.5% by 20-mol/l ADP light
ransmittance aggregometry; 236 P2Y12 reaction units mea-
ured by VerifyNow P2Y12 assay; and 80.5% aggregation by
lateletworks (Helena Laboratories, Beaumont, Texas) all
orrelated with the occurrence of the composite primary end
oint, with an area under the curve of 0.62 for each assay.
he addition of high on-treatment platelet reactivity as
easured by the noted platelet assays to more classical
linical and procedural risk factors improved the area under
he curve to 0.73 (82).
Each of these studies may thus provide a target level of
latelet reactivity for future investigations, similar to the
nternational normalized ratio used for warfarin therapy.
he consistent findings across multiple investigations sup-
ort the crucial role of high on-treatment reactivity in the
tiology of ischemic events after PCI, including stent throm-
osis, and suggest the existence of a threshold level of platelet
eactivity below which ischemic events may be prevented
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Studies Linking High On-Treatment Platelet Reactivity to ADP and
Clopidogrel Nonresponsiveness to Post-PCI Adverse Clinical Event Occurrence
Study (Ref. #) Patients (n) Treatment Methods Definition Clinical Relevance
Barragan et al. (58) PCI (46) 250 mg qd TLP or
CLP 75 mg qd
VASP-PRI 50% VASP-PRI 1 ST
Gurbel et al. (55) Elective PCI (192) 300-mg LD  75 mg
qd CLP /– EPT
5-mol/l ADP-LTA HPR  75th percentile post-PCI
aggregation
1 6-month post-PCI
events, OR: 2.7
Matetzky et al. (59) PCI/STEMI
(60)
300-mg LD  75 mg
qd CLP /– EPT
5-mol/l ADP-LTA Reduction in platelet aggregation
Upper quartile
1 6-month cardiac
events
Gurbel et al. (60) Elective PCI (120) 300-mg LD
CLP /– EPT
5-mol/l ADP-LTA Mean periprocedural platelet
aggregation 50%
1 Periprocedural
myonecrosis
Gurbel et al. (61) Elective PCI (200) 300-/600-mg LD
CLP /– EPT
5-mol/l ADP-LTA Mean periprocedural platelet
aggregation 40%
1 Periprocedural
myonecrosis
Bliden et al. (54) Elective PCI (100) 75 mg qd CLP 5-mol/l ADP-LTA 50% platelet aggregation 1 1-yr post-PCI events
Lev et al. (43) Elective PCI (150) 300-mg CLP LD 5- and 20-mol/l ADP-LTA Baseline—post-treatment
aggregation 10%
1 Periprocedural
myonecrosis
Blindt et al. (62) High risk for ST/PCI
(99)
75 mg qd for 6 months VASP-PRI (72–96 h after
stenting)
48% PRI (ROC) 1 6-month ST
Cuisset et al. (63) NSTEMI/ACS/PCI
(190)
600-mg CLP LD 6 h
before PCI
10-mol/l ADP-LTA VASP-PRI HPR 70% post-treatment LTA 1 Periprocedural
myonecrosis
Frere et al. (64) NSTEMI/ACS/PCI
(195)
600-mg CLP LD 6 h
before PCI
10-mol/l ADP-LTA HPR (ROC) 70% post-treatment
LTA 53% VASP-PRI
1 30-day post-PCI
events MACE 
stroke
Geisler et al. (65) CAD/PCI (379) 600-mg CLP LD 6 h
before PCI
20-mol/l ADP-LTA Clopidogrel low responders 
30% platelet inhibition
1 3-month MACE and
death OR: 4.9
Geisler et al. (66) CAD/PCI (1,092) 600-mg CLP LD 6 h
before PCI
 75 mg qd
20-mol/l ADP-LTA
Residual aggregation
measured after 5 min
Upper quartile 1 30-day MACE
Hochholzer et al. (67) Elective PCI (802) 600-mg CLP LD
2 h before PCI 
75 mg qd
5-mol/l ADP-LTA Residual
aggregation measured
after 5 min
Platelet aggregation above
median
1 30-day MACE OR: 6.7
Price et al. (68) PCI (380) 600-mg CLP LD
12 h before PCI or
75 mg qd 5 days
VerifyNow P2Y12 assay HPR  post-treatment 235
PRU (ROC)
1 6-month post-PCI
events including ST
Gurbel et al. (69) Elective PCI (297) 300-/600-mg LD/
75 mg qd CLP
/– EPT
5- and 20-mol/l ADP-LTA HPR  post-procedural (ROC)
46% 5-mol/l ADP
59% 20-mol/l ADP
1 2-yr ischemic events
5-mol/l ADP OR: 3.9
20-mol/l ADP OR: 3.8
Gurbel et al. (70) Stenting
(120)
75-mg qd CLP
5 days
5- and 20-mol/l ADP-LTA HPR 75th percentile of
platelet reactivity
5-mol/l ADP  50%
20-mol/l ADP  65%
1 ST
Buonamici et al. (71) PCI/DES
(804)
600-mg LD 
75 mg qd for
6 months
10-mol/l ADP-LTA HPR 70% aggregation 1 ST HR: 3.08
Bonello et al. (72) PCI/stenting (144) 300-mg LD 24 h VASP-PRI 50% PRI (ROC) 1 6-month post-PCI
MACE
Cuisset et al. (73) PCI/SA (120) 600-mg LD 12 h
before PCI
VerifyNow P2Y12 assay 1 Platelet reactivity 1 Post-PCI myonecrosiscontinued on next page
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September 14, 2010:919–33 High On-Treatment Platelet Reactivity62,64,68,69,72,75,80–82). Most importantly, the observed cut-
ff values for platelet reactivity noted previously had a very high
egative predictive value for thrombotic/ischemic event occur-
ence, an observation of potential great clinical importance. How-
ver, the positive predictive value is fairly low for all assays.
his is consistent with the fact that although it is a major
eterminant of thrombotic events, high on-treatment platelet
eactivity is not the sole factor responsible for these events.
ersonalized Antiplatelet
herapy: Preliminary Prospective Studies
ollowing the demonstration of a link between high on-
reatment platelet reactivity in patients undergoing PCI
ogether and thrombotic/ischemic events, several studies
ave aimed to lower the level of platelet reactivity by
odifying therapy. These studies have demonstrated that
latelet reactivity to ADP on standard clopidogrel therapy
Table 1
Continued
Study (Ref. #) Patients (n) Treatment
Migliorini et al. (74) PCI/DES/ULMD
(215)
600-mg LD 
75 mg qd for
12 months
10-m
Marcucci et al. (75) PCI/ACS
(683)
600-mg LD
 75 mg qd
Verify
Bonello et al. (76) PCI/stenting
(162)
600 mg repeated dose
until PRI 50%
VASP
Bonello et al (77) PCI/stenting
(214)
600-mg repeated dose
until PRI 50%
VASP
Valgimigli et al. (78) Elective PCI
(1,277)
600-mg LD before PCI Verify
P2
Patti et al. (79) PCI (160) 600-mg LD or
75 mg qd 5 days
Verify
Sibbing et al. (80) PCI/DES
(1,608)
600-mg LD before PCI 6.4-
an
Cuisset et al. (81) NSTEMI/stenting
(598)
600-mg LD 12 h
before PCI
10-m
VA
Breet et al. (82) Elective PCI
(1,069)
75-mg qd 5 days
300-mg LD 1 day
600-mg LD
20-
Verify
20-
Pla
Befor
CS  acute coronary syndromes; ADP  adenosine diphosphate; ARU  aspirin resistance
ardiovascular; DES  drug-eluting stent; EPT  eptifibatide; HPR  high on-treatment platelet re
dverse cardiac events; MI  myocardial infarction; NSTEMI  non–ST-segment elevated myoca
nce daily; ROC  receiver-operator characteristic curve; SA  stable angina; ST  stent thromb
ain disease; VASP-PRI  vasodilator stimulated phosphoprotein—platelet reactivity index.an be lowered by using higher loading or maintenance eoses of clopidogrel, the addition of cilostazol, switching to
ore potent alternative P2Y12 receptor blockers such as
rasugrel or ticagrelor (AstraZeneca, Wilmington, Dela-
are), and by adding elinogrel or GP IIb/IIIa inhibitors
76–78,85–93). An improved outcome with altered therapy
as observed in some of these studies (76–78,93).
In 2 small multicenter trials that employed the VASP-
hosphorylation assay, tailored incremental loading doses of
lopidogrel further reduced on-treatment platelet reactivity
elow the previously noted threshold and were effective in
educing subsequent major adverse cardiac events without
ncreasing Thrombolysis In Myocardial Infarction (TIMI)
ajor or minor bleedings. However, it must be noted that
bout 5% of patients remain resistant to clopidogrel even after
epeated loading doses of 600 mg (76,77). Similarly, following
hese findings, 2 other studies (82,91) have suggested that the
elective administration of platelet GP IIb/IIIa receptor block-
ethods Definition Clinical Relevance
DP-LTA HPR 70% aggregation 1 3-yr cardiac death
and ST
HR CV death: 3.82
HR ST: 3.69
2Y12 assay HPR 240 PRU 12-month ischemic event
HR CV death: 2.55
HR nonfatal MI: 3.36
50% VASP-PRI 2 1-month ischemic
event
50% VASP-PRI 2 Early ST and MACE
(OR: 9.4)
spirin and
ssay
235 PRU
550 ARU
1 Post-PCI myonecrosis
2Y12 assay HPR 240 PRU (Pre-PCI) 1 1-month major
cardiovascular event
occurrence
ADP Multiplate Upper quintile (416 AU/min)
(ROC)
1 1-month definite ST
(OR: 9.4)
DP-LTA 67% aggregation (ROC) 1 ST
DP-LTA
2Y12
DP
orks
42.9% 5-mol/l ADP (ROC)
64.5% 20-mol/l ADP
236 PRU
80.5% Plateletworks
OR for 1-yr death, MI,
ST, and stroke
5-mol/l ADP: 2.09
20-mol/l ADP: 2.05
VerifyNow: 2.53
Plateletworks: 2.22
AU  arbitrary aggregation units; CAD  coronary artery disease; CLP  clopidogrel; CV 
; HR  hazard ratio; LD  loading dose; LTA  light transmittance aggregometry; MACE  major
farction; OR  odds ratio; PCI  percutaneous intervention; PRU  P2Y12 reaction units; qd 
TEMI  ST-segment elevated myocardial infarction; TLP  ticlopidine; ULMD unprotected leftM
ol/l A
Now P
-PRI
-PRI
Now a
Y12 a
Now P
mol/l
alyzer
ol/l A
SP-PRI
mol/l A
Now P
mol/l A
teletw
e PCI
units;
activity
rdial in
osis; Srs to patients undergoing elective PCI who were identified as
h
c
p
T
i
b
O
P
L
o
p
A viations
C
928 Bonello et al. JACC Vol. 56, No. 12, 2010
High On-Treatment Platelet Reactivity September 14, 2010:919–33aving high on-treatment platelet reactivity following an oral
lopidogrel loading dose was effective in reducing subsequent
ost-PCI ischemic events without increased bleeding rates.
hese studies are the first to suggest that the cutoff value
dentifying patients at increased risk of thrombotic events could
e used to tailor therapy and lead to an improved outcome.
Table 2
Studies Linking High On-Treatment Platelet Rea
to Ischemic Events Based on ROC Curve With a
Study (Ref. #) Assay Cutoff Valu
Price et al. (68) VerifyNow P2Y12 assay 235 PRU
Gurbel et al. (69) LTA 46% 5-mol/l A
59% 20-mol/
Blindt et al. (62) VASP-PRI 48% PRI
Frere et al. (64) LTA
VASP-PRI
70% 10-mol/
53% PRI
Bonello et al. (72) VASP-PRI 50% PRI
Marcucci et al.
(75)
VerifyNow P2Y12 assay 240
Sibbing et al. (80) Multiplate analyzer-ADP 468 AU/min
6.4-mol/l ADP
Cuisset et al. (81) LTA 67% 10-mol/
Breet et al. (82) LTA
VerifyNow P2Y12 assay
Plateletworks
42.9% 5-mol/
64.5% 20-mo
236 PRU
80.5% 20-mo
UC  area under the curve; CVD  cardiovascular disease; NA  not addressed; other abbre
Table 3
Ongoing Clinical Studies Based Platelet Reactivity
Study
ClinicalTrials.gov
Identifier
GRAVITAS Gauging Responsiveness With a VerifyNow
Assay—Impact on Thrombosis and Safety
NCT00645918
ARCTIC Double Randomization of a Monitoring
Adjusted Antiplatelet Treatment Versus a
Common Antiplatelet Treatment for DES
Implantation, and Interruption Versus
Continuation of Double Antiplatelet Therapy
NCT00827411
DANTE Dual Antiplatelet Therapy Tailored on the
Extent of Platelet Inhibition
NCT00774475
TOPAS -1 Tailoring of Platelet Inhibition to Avoid Stent
Thrombosis
NCT00914368
TRIGGER-PCI Testing Platelet Reactivity In Patients
Undergoing Elective Stent Placement on
Clopidogrel to Guide Alternative Therapy
With Prasugrel
NCT00910299ABG  coronary artery bypass graft; MD  maintenance dose; TVR  target vessel revascularizationngoing Studies of
ersonalized P2Y12 Inhibitor Therapy
arger clinical trials aimed at confirming the potential benefit
f tailored doses of clopidogrel according to on-treatment
latelet reactivity assessed by VerifyNow are currently recruit-
ty
cific Cutoff Value
End Point AUC Odds Ratio
6-month post-PCI
CVD  MI  ST
0.71 NA
2-year post-PCI MACE 0.77
0.78
3.9
3.8
6-month ST 0.79 1.16
1-month post-PCI
MACE  stroke
0.74
0.73
NA
6-month post-PCI MACE 0.55 NA
1-yr CV death and
nonfatal MI
0.66 2.38 CV death
2.76 nonfatal MI
30-day ST 0.78 12.0
1-month ST 0.69 5.8
1-yr death, MI, ST, and
stroke
0.63
0.62
0.62
0.61
2.09
2.05
2.53
2.22
as in Table 1.
easurement by VerifyNow Assay
able or NSTEMI/PCI Outcome Clopidogrel Therapy
ive or ACS/PCI/DES
,783)
6-month CV death, nonfatal MI,
or ST
75 mg qd vs. 150 mg qd
ive PCI/DES
,500)
12-month composite end point
of death, MI, stroke, urgent
revascularization, ST
Therapy based on MD’s
performance
ble or NSTEMI/PCI
42)
6- and 12-month CV death,
nonfatal MI, TVR by PCI or
CABG
75 mg qd vs. 150 mg qd
us PCI or stenting
CAD (450)
6-month ST 600-mg LD 75 mg qd for
6 months
atients (2,150) CV death, nonfatal MI Prasugrel 60/10 mg vs.
clopidogrel
600/75 mgctivi
Spe
e
DP
l ADP
l ADP
l ADP
l ADP
l/l ADP
l/l ADPM
Unst
Elect
(2
Elect
(2
Unsta
(4
Previo
for
PCI p; other abbreviations as in Table 1.
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September 14, 2010:919–33 High On-Treatment Platelet Reactivityng patients (Table 3) (94). The clinical benefit of achieving
ower levels of on-treatment platelet reactivity was suggested by
he TRITON–TIMI 38 (Trial to Assess Improvement in
herapeutic Outcomes by Optimizing Platelet Inhibition
ith Prasugrel–Thrombolysis In Myocardial Infarction 38)
95) and the PLATO (Platelet Inhibition and Patient
utcomes) trials (96). In TRITON–TIMI 38, prasugrel, a
hird-generation thienopyridine associated with faster and
ower on-treatment platelet reactivity than clopidogrel, was
n turn associated with a lower prevalence of thrombotic
vents in ACS patients treated with PCI (95,97). However,
rasugrel was associated with greater bleeding rates in the
RITON–TIMI 38 trial that may be related to excessively
ow platelet reactivity in selected patients (97). In the
LATO study, ticagrelor, the first oral nonthienopyridine
eversible P2Y12 inhibitor that provides a faster platelet
nhibition and lower on-treatment platelet reactivity than
lopidogrel was also associated with lower rates of ischemic
vents in an ACS population. Similar to the results of
RITON–TIMI 38, increased bleedings in ACS patients
ndergoing PCI were also noted in the ticagrelor group
95–97). These findings are consistent with the hypothesis
hat lower levels of platelet aggregation are associated with
educed ischemic events but increased bleeding risk. In the
LATO study, a similar bleeding event rate in patients
ndergoing coronary artery bypass grafting where ticagrelor
herapy was discontinued within 3 days before surgery was
bserved (96). This was supported by the observation that
icagrelor was associated with faster offset of antiplatelet
ffects compared with clopidogrel therapy despite superior
latelet inhibition in the ONSET/OFFSET (Randomized
ouble-Blind Assessment of the Onset and Offset of the
ntiplatelet Effects of Ticagrelor Versus Clopidogrel in
atients With Stable Coronary Disease) study (17). More-
ver, in the RESPOND (Response to Ticagrelor in Clopi-
ogrel Nonresponders and Responders and the Effect of
witching Therapies) study (93), ticagrelor therapy was
ssociated with uniform and superior platelet inhibition in
oth previously identified clopidogrel responders and non-
esponders, and that inhibition, in turn, was associated with
n extremely low prevalence of high on-treatment platelet
eactivity. In addition, another novel reversible P2Y12 re-
eptor blocker, elinogrel, has been shown to be associated
ith enhanced platelet inhibition when administered to
elected patients with high platelet reactivity during stan-
ard clopidogrel therapy. Moreover, the antiplatelet effect of
linogrel was completely reversible within 24 h (92). The
reviously discussed alternative therapies may provide im-
ortant advances to attenuated ischemic events occurrence,
articularly in selected patients with high platelet reactivity
n standard clopidogrel treatment. Dose adjustments based en objective measurements of platelet reactivity may reduce
he prevalence of bleeding. Reversibility may facilitate the
anagement of patients requiring unanticipated surgery.
he results of TRITON–TIMI 38 and PLATO suggest
hat there may be a fine balance between ischemic event
ccurrences and bleeding in patients treated with P2Y12
eceptor blockers. Consistently tailored P2Y12 receptor
lockade has the potential to improve outcome.
2Y12 Inhibitor Therapeutic Window
s platelet-mediated ischemic events appear to be clustered
n the upper tertile or quartile of on-treatment platelet
eactivity (i.e., above the optimal cut points previously
dentified), there may exist a “therapeutic window” for
2Y12 receptor antagonist therapy that is associated with
oth an optimal reduction in thrombotic events as well as a
ow rate of major bleeding. The identification of a specific
hreshold for platelet reactivity that confers protection
gainst thrombotic events and yet also limits bleeding
ollowing PCI is a crucial area of investigation, particularly
n light of the increasing availability of platelet point-of-care
ssays as well as the widening choice of P2Y12 receptor
ntagonists (7,60) (Fig. 3). At this time, there have been no
efinitive studies confirming a cut point of platelet reactivity
o ADP associated with bleeding risk. However, recent obser-
ational data have emerged showing an association of an
Figure 3
Post-PCI Ischemic/Thrombotic Clinical Events
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High On-Treatment Platelet Reactivity September 14, 2010:919–33n-hospital bleeding events in clopidogrel-treated patients un-
ergoing PCI (98–100). Moreover, the advent of more potent
ntiplatelet drugs that target the P2Y12 receptor—such as prasug-
el and ticagrelor, sets the need to study the relationship of
ntiplatelet treatment and risk for bleeding more thoroughly.
uture Considerations
t is unknown whether on-treatment platelet reactivity cut
oints associated with risk for periprocedural events are the
ame as those associated with long-term risk. Although similar
ut points have been reported, the optimal platelet reactivity
arget may vary with respect to the time following the PCI
rocedure. For example, lower on-treatment platelet reactivity
ay be optimal in the early period following ACS and/or PCI,
hereas the same low level may not provide the same clinical
dvantage 6 months later due to excessive bleeding. Also, the
ptimal level of platelet reactivity may differ between the
ettings of elective as compared to emergent PCI. Another
actor that must be considered is that antiplatelet therapy
esponsiveness has been reported to improve over time follow-
ng PCI, which may result in lower on-treatment platelet
eactivity (6). Finally, the comparative utility of platelet func-
ion versus genetic testing should be investigated prospectively
n order to determine whether these strategies are complemen-
ary or stand-alone methods to identify the high-risk patients.
onclusions
he absolute level of platelet reactivity during treatment (i.e.,
n-treatment platelet reactivity) is proposed by the consensus
f all the authors to be a better measure of thrombotic risk than
esponsiveness to clopidogrel. Currently available evidence
upports the concept of a threshold for on-treatment platelet
eactivity that may be used to stratify patient risk for ischemic/
hrombotic events following PCI, including stent thrombosis.
t the present time, high on-treatment platelet reactivity in the
etting of PCI has been defined by ROC analyses using the
ollowing criteria: 1) PRI50% by VASP-P analysis; 2)235
o 240 P2Y12 reaction units by VerifyNow P2Y12 assay; 3)
46% maximal 5-mol/l ADP-induced aggregation; and 4)
468 arbitrary aggregation units/min in response to ADP by
ultiplate analyzer (68,69,72,80) (Table 2). However, there
re no large-scale clinical studies to date demonstrating that the
djustment of antiplatelet therapy based on any of these cut
oints improves clinical outcomes. Finally, PCI patients with
iabetes and patients with ACS treated medically as compared
o those treated with PCI may have different high on-
reatment platelet reactivity cut points (84).
Ongoing studies with the VerifyNow P2Y12 assay are
nderway to determine whether individually tailoring anti-
latelet therapy will improve clinical outcomes after PCI.
hese studies will also investigate the relationship of platelet peactivity to bleeding events. Currently, platelet function
esting may be considered in determining an antiplatelet
trategy in patients with a history of stent thrombosis and in
atients prior to undergoing high-risk PCI. However, until
he results of large-scale trials of personalized antiplatelet
herapy are available, the routine use of platelet function
easurements in the care of patients with cardiovascular
isease cannot be recommended.
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